enterprise

SeaCrest Wealth Management LLC Boosts Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON) – Defense World



SeaCrest Wealth Management LLC raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXONFree Report) by 6.8% in the 4th quarter, Holdings Channel reports. The fund owned 1,565 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Axon Enterprise were worth $382,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Capital International Investors raised its stake in shares of Axon Enterprise by 605.2% during the 1st quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock worth $366,449,000 after buying an additional 2,283,343 shares in the last quarter. Sands Capital Management LLC raised its stake in shares of Axon Enterprise by 101.6% during the 2nd quarter. Sands Capital Management LLC now owns 1,993,126 shares of the biotechnology company’s stock worth $388,899,000 after buying an additional 1,004,556 shares in the last quarter. BlackRock Inc. raised its stake in shares of Axon Enterprise by 11.7% during the 1st quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company’s stock worth $1,872,883,000 after buying an additional 870,481 shares in the last quarter. Norges Bank purchased a new position in shares of Axon Enterprise during the 4th quarter worth approximately $102,920,000. Finally, State Street Corp grew its holdings in shares of Axon Enterprise by 22.6% in the 2nd quarter. State Street Corp now owns 2,915,214 shares of the biotechnology company’s stock worth $568,817,000 after acquiring an additional 538,119 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 0.9 %

Shares of AXON opened at $312.88 on Friday. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $23.61 billion, a P/E ratio of 136.04 and a beta of 0.93. The stock’s fifty day simple moving average is $285.73 and its 200 day simple moving average is $247.10. Axon Enterprise, Inc. has a twelve month low of $175.37 and a twelve month high of $325.63.

Axon Enterprise (NASDAQ:AXONGet Free Report) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.29. The business had revenue of $432.14 million for the quarter, compared to analyst estimates of $418.97 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. On average, equities research analysts forecast that Axon Enterprise, Inc. will post 2.43 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 35,400 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $251.68, for a total value of $8,909,472.00. Following the transaction, the president now directly owns 309,564 shares of the company’s stock, valued at $77,911,067.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $285.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. TheStreet cut Axon Enterprise from a “b” rating to a “c+” rating in a report on Tuesday, February 27th. Argus assumed coverage on Axon Enterprise in a report on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target on the stock. Robert W. Baird upped their price target on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. Finally, Needham & Company LLC upped their price target on Axon Enterprise from $240.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $301.73.

Get Our Latest Analysis on AXON

Axon Enterprise Profile

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Read More

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXONFree Report).

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)



Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.